Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Document first published:
Page updated:
Topic:
Publication type:

Rituximab is recommended to be available as a treatment option through routine commissioning for nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children within the criteria set out in this document.

This policy is restricted to certain age groups as the evidence review did not identify evidence to support the efficacy of rituximab in pre-pubescent children for this indication.

 

Document

Clinical commissioning policy: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Clinical commissioning policy: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 313 KB
  • 18 pages

Summary

Published September 2021.

Document

Clinical priorities advisory group summary report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Clinical priorities advisory group summary report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 217 KB
  • 10 pages

Document

Engagement report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Engagement report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 178 KB
  • 6 pages

Document

Equality and health inequalities impact assessment: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Equality and health inequalities impact assessment: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 185 KB
  • 20 pages

Document

Evidence review: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Evidence review: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 487 KB
  • 37 pages

Document

Public health evidence report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Public health evidence report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 113 KB
  • 3 pages

Document

Clinical panel report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Clinical panel report: rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

  • PDF
  • 132 KB
  • 4 pages